Journal
CIRCULATION RESEARCH
Volume 123, Issue 10, Pages 1121-1123Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.118.313842
Keywords
atherosclerosis; immune system; inflammation; thrombosis; vaccine
Funding
- Eisner Foundation
- Heart Foundation
- Spielberg Cardiovascular Research Fund
- Petersen Foundation
- Steinberg Foundation
- Cardiovax, Inc.
- Annenberg Foundation
Ask authors/readers for more resources
Atherosclerotic cardiovascular disease (ACVD) affects > 82 million people in the United States. Lipid-lowering therapy is the major current strategy in managing ACVD and has reduced cardiovascular events by about 30 to 50%, leaving a substantial percentage of patients who continue to suffer ischemic events. Inflammation and immune system activation has been implicated in the pathophysiology of athero-thrombosis. The CANTOS trial (The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) provided the first clinical evidence demonstrating the efficacy of targeting inflammation in reducing cardiovascular events. Modulation of the immune system is another potentially attractive option for management of ACVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available